1. How to submit my research paper? What’s the process of publication of my paper?
The journal receives submitted manuscripts via email only. Please submit your research paper in .doc or.pdf format to the submission email: ijpmbs@ejournal.net.
You’ll be given a paper number if your submission is successful. Your paper then will undergo peer review process, which may take approximately one and a half months under normal circumstances, three tops.
After blind peer review, you will receive the notification letter with the review result of your paper...
2. Can I submit an abstract?
The journal publishes full research papers.[Read More]
 
IJPMBS 2026 Vol.15(4): 184-187
doi: 10.18178/ijpmbs.15.4.184-187

The Use of Folate Receptor Alpha-targeted Nanotechnology in Ovarian Cancer Diagnosis and Treatment

Briny Yu Xin Ya Xiao
The Henrietta Barnet School, London, United Kingdom
Email: Brineyxiao1@gmail.com

Manuscript received July 27, 2026; accepted October 10, 2026; published November 17, 2026.

Abstract—Ovarian cancer is a major gynecological disease that has poor survival outcomes due to its frequent diagnosis at late stages of malignancy. As ovarian carcinomas overexpress the folate receptor alpha, FRα can be used as a target for improved diagnosis and therapeutic effects. This review examines recent studies on FRα-targeted nanotechnological approaches to improve ovarian cancer diagnosis through enhanced imaging contrast and treatment through controlled drug delivery. Specifically, diagnostic approaches include FA-PEG-FePt nanoliposomes and SPIONs, which enhance MRI contrast, and antibody-functionalized protein nanoparticles, which improve fluorescence imaging. In contrast, therapeutic approaches include FA-PEG-FePt/DDP nanoliposomes, folate-engineered chitosan nanoparticles, and extracellular vesicles, which provide high specificity in drug delivery, improved bioavailability, and reduced drug resistance. Nanomedicine is a promising approach to improving outcomes for patients with ovarian cancer, as it enhances diagnostic sensitivity, reduces toxicity, and improves the effectiveness of chemotherapeutic agents. However, clinical applications of nanotechnology are limited by off-target effects, immunogenicity, and tumor heterogeneity, suggesting that FRα-targeted nanotechnology has a promising but largely uncertain potential in ovarian cancer treatment. Ultimately, FRα-targeted nanotechnology provides a powerful platform for ovarian cancer diagnosis and treatment, yet scientists must resolve critical challenges in toxicity to ensure effective patient outcomes.
 
Keywords—nanotechnology, ovarian cancer, folate receptor alpha, drug delivery, theragnostic

Cite: Briny Yu Xin Ya Xiao, "The Use of Folate Receptor Alpha-targeted Nanotechnology in Ovarian Cancer Diagnosis and Treatment," International Journal of Pharma Medicine and Biological Sciences, Vol. 15, No. 4, pp. 184-187 2026.

Copyright © 2026 by the authors. This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Copyright © 2012-2026. International Journal of Pharma Medicine and Biological Sciences. Unless otherwise stated.
​E-mail: ijpmbs@ejournal.net
Published by